| Bioactivity | S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC50 value of 3.04 nM. S19-1035 can be used for the research of tumor[1]. | |||||||||
| Target | IC50: 3.04 nM (AKR1C3) | |||||||||
| Invitro | S19-1035 对 AKR1C3 具有抑制活性，其 IC50 值为 3.04 nM[1]。S19-1035 (0-100 μM; 72 h or 96 h) 的细胞毒性较小，单独使用时抗肿瘤作用有限[1]。S19-1035 (10 μM; 8 days) 显著逆转耐药乳腺癌细胞株的多柔比星（DOX）耐药性[1]。 Cell Cytotoxicity Assay[1] Cell Line: | |||||||||
| Name | S19-1035 | |||||||||
| Formula | C19H17ClN2O3 | |||||||||
| Molar Mass | 356.80 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Yang Liu, et al. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer. Eur J Med Chem. 2022 Dec 13;247:115013. |